MoMed Biotech's latest experiment results show that the PROTAC molecule designed and developed by the R&D team can significantly reduce the level of ERα protein in MCF-7 cells of human breast cancer. The best degradation agent, DC50, has a value of 0.67 nM, which is the same as the degradation level achieved by the ARV-471 developed by Arvinas (entering clinical phase II, DC50=1.8 nM).

Momed Biotech (Hangzhou) Biotechnology Co., Ltd., a process spanning nearly five months, saw the completion of its over 1000m2 office renovation project, which commenced in December 2022. In April 2023, much anticipated by many, Chenzhu Technology officially relocated to 60 Hongfeng Road, Linping District, Hangzhou.

In August 2022, Professor Bai Chen was interviewed by ' China High-tech ' magazine. He described his experience in the field of macromolecular mechanism research of drug targets and his vision and goals for the future of the biomedical industry. The relevant report is published in the ' China High-tech ' magazine in August 2022.

On June 28, Professor Bai Chen was invited to participate in the " Innovation Linping Wisdom Hongfeng " High-efficiency Achievement Transformation and Innovation Summit Forum at the Linping venue of the Sixth World Growth Conference in Hangzhou. This forum is guided by the China Association for Science and Technology, sponsored by the Hangzhou Municipal People 's Government, the Zhejiang Provincial Committee of the People 's Republic of China, and the China Investment Development Promotion Association. It is undertaken by the people 's government of Linping District, Linping National Economic